Tag: BBV152
Covaxin P3 data published in Lancet, overall 77.8% efficacy confirmed
This first publication of the data shows COVAXIN has 93.4% efficacy against severe COVID-19 disease, 77.8% overall efficacy, 63.6% efficacy against asymptomatic disease and 65.2% efficacy against the Delta variant in the Phase 3 clinical trial of 25,798 participants..........................
Bharat Biotech’s COVAXIN Phase 3 results show interim clinical efficacy of...
Data from 25,800 participants that received the COVAXIN vaccine or placebo in a 1:1 ratio showed that the vaccine candidate was well-tolerated. It demonstrated 81% interim efficacy in preventing COVID-19 after the second dose....................